budesonide + formoterol + glycopyrronium: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
budesonide + formoterol + glycopyrronium: clinical details
Prescribing considerations
- Confirm that the patient meets the licensed COPD indication and is not using the inhaler as rescue therapy.
- Review inhaler technique, adherence and coordination; consider a compatible spacer where appropriate.
- Use caution with significant cardiovascular disease, QT prolongation, thyrotoxicosis, diabetes, narrow-angle glaucoma, urinary retention or symptomatic prostatic enlargement.
- In severe renal or hepatic impairment, use only where expected benefit outweighs risk.
- Remain alert to pneumonia, particularly where additional risk factors are present.
- Consider cumulative systemic corticosteroid exposure, adrenal suppression, bone health and ocular effects.
Contraindications and cautions
- Hypersensitivity to budesonide, formoterol, glycopyrronium or any excipient.
Monitoring
- COPD symptoms, exacerbations, reliever use and inhaler technique.
- Features of pneumonia or paradoxical bronchospasm.
- Blood glucose in patients with diabetes.
- Potassium where clinically indicated, especially with hypoxia or potassium-lowering treatments.
- Cardiovascular symptoms and rhythm in susceptible patients.
- Urinary retention, acute narrow-angle glaucoma symptoms and visual disturbance.
- Systemic corticosteroid effects where exposure is prolonged or cumulative.
Clinical pharmacology
Budesonide provides local glucocorticoid anti-inflammatory activity. Formoterol is a selective long-acting beta2 agonist. Glycopyrronium is a competitive, reversible long-acting muscarinic antagonist acting principally at airway M3 receptors.
Formulation and product differences
- The selected product is a pressurised inhalation suspension with a dose indicator.
- It requires shaking and product-specific priming.
- It can be used with compatible spacer devices, including AeroChamber Plus Flow-Vu.
- The canister, actuator and mouthpiece are product-specific and should not be interchanged with another inhaler.
budesonide + formoterol + glycopyrronium preparations and strengths
Inhaled preparation
Route: Inhaled
Strengths: 5 micrograms + 7.2 micrograms + 160 micrograms
budesonide + formoterol + glycopyrronium interactions
Check all inhalers, eye drops, prescribed treatments and non-prescription products with a healthcare professional. Important interactions include:
Other long-acting beta2 agonists or antimuscarinic inhalers
Combined use is not recommended because bronchodilator and anticholinergic adverse effects may increase.
Beta-blockers, including timolol eye drops
They may weaken or block formoterol's bronchodilator effect and require clinical review.
Strong CYP3A inhibitors, including itraconazole, ketoconazole, ritonavir and cobicistat
They can increase budesonide exposure and the risk of systemic corticosteroid effects.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.